Survival Benefit and Phenotypic Improvement by Hamartin Gene Therapy in a Tuberous Sclerosis Mouse Brain Model

Neurobiology of Disease - United States
doi 10.1016/j.nbd.2015.04.018
Full Text
Abstract

Available in full text

Categories
Neurology
Date
Authors
Publisher

Elsevier BV

Related search

Equivalent Benefit of mTORC1 Blockade and Combined PI3K-mTOR Blockade in a Mouse Model of Tuberous Sclerosis

Molecular Cancer
Cancer ResearchOncologyMolecular Medicine
2009English

Equivalent Benefit of Rapamycin and a Potent mTOR ATP-Competitive Inhibitor, MLN0128 (INK128), in a Mouse Model of Tuberous Sclerosis

Molecular Cancer Research
Cancer ResearchOncologyMolecular Biology
2013English

Analysis of a Mouse Skin Model of Tuberous Sclerosis Complex

PLoS ONE
Multidisciplinary
2016English

Rapamycin Prevents Epilepsy in a Mouse Model of Tuberous Sclerosis Complex

Annals of Neurology
Neurology
2008English

Sexually Divergent Mortality and Partial Phenotypic Rescue After Gene Therapy in a Mouse Model of Dravet Syndrome

Human Gene Therapy
Molecular MedicineGeneticsMolecular Biology
2020English

Photodynamic Therapy for Exudative Hamartoma in Tuberous Sclerosis

Archives of Ophthalmology
2006English

Tuberous Sclerosis.

Archives of Disease in Childhood
Child HealthPediatricsPerinatology
1995English

Tuberous Sclerosis

2019English

Tuberous Sclerosis–A Neurocutaneous Disorder

Northern International Medical College Journal
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy